

US Family Health Plan

Prior Authorization Request Form for relugolix (**Orgovyx**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Medical documentation may be required. Failure to provide could result in denial.

Step 1 Please complete patient and physician information (please print):

Patient Name: _____ Address: _____ Sponsor ID #: _____ Date of Birth: _____	Physician Name: _____ Address: _____ Phone #: _____ Secure Fax #: _____
--	--

Step 2 Please complete the clinical assessment:

1. The following agents are available without a prior authorization: leuprolide acetate IM (Lupron Depot), leuprolide acetate SQ (Eligard), and degarelix SQ (Firmagon). Please consider changing the prescription to one of these agents.	<input type="checkbox"/> Acknowledged Proceed to Question 2		
2. Is the patient 18 years of age or older?	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> Yes Proceed to Question 3 </td> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> No STOP Coverage not approved </td> </tr> </table>	<input type="checkbox"/> Yes Proceed to Question 3	<input type="checkbox"/> No STOP Coverage not approved
<input type="checkbox"/> Yes Proceed to Question 3	<input type="checkbox"/> No STOP Coverage not approved		
3. Is the requested medication prescribed by or in consultation with an oncologist or urologist?	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> Yes Proceed to Question 4 </td> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> No STOP Coverage not approved </td> </tr> </table>	<input type="checkbox"/> Yes Proceed to Question 4	<input type="checkbox"/> No STOP Coverage not approved
<input type="checkbox"/> Yes Proceed to Question 4	<input type="checkbox"/> No STOP Coverage not approved		
4. What is the indication or diagnosis? Note: Non-FDA-approved uses are not approved including in women for endometrial thinning, endometriosis, and uterine leiomyomata (fibroids).	<input type="checkbox"/> Advanced prostate cancer - Proceed to Question 7 <input type="checkbox"/> Other - Proceed to Question 5		
5. Please provide the indication or diagnosis.	_____ Proceed to question 6		
6. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> Yes Sign and date below </td> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> No STOP Coverage not approved </td> </tr> </table>	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved
<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No STOP Coverage not approved		
7. Has the patient tried and failed an injectable formulation (for example, subcutaneous injection or implant, intramuscular injection)?	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> Yes Sign and date below </td> <td style="width: 50%; text-align: center; padding: 5px;"> <input type="checkbox"/> No Proceed to Question 8 </td> </tr> </table>	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to Question 8
<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Proceed to Question 8		

USFHP Prior Authorization Request Form for
relugolix (**Orgovyx**)

8. Is the patient unable to use an injectable formulation (for example, subcutaneous injection or implant, intramuscular injection)?

Yes
Sign and date below

No
STOP
Coverage not approved

Step 3 I certify the above is true to the best of my knowledge. Please sign and date.

Prescriber Signature

Date

[02 March 2022]